AU2016243516A1 - Methods and materials for reducing amyloid beta levels within a mammal - Google Patents

Methods and materials for reducing amyloid beta levels within a mammal Download PDF

Info

Publication number
AU2016243516A1
AU2016243516A1 AU2016243516A AU2016243516A AU2016243516A1 AU 2016243516 A1 AU2016243516 A1 AU 2016243516A1 AU 2016243516 A AU2016243516 A AU 2016243516A AU 2016243516 A AU2016243516 A AU 2016243516A AU 2016243516 A1 AU2016243516 A1 AU 2016243516A1
Authority
AU
Australia
Prior art keywords
potato polysaccharide
potato
polysaccharide preparation
mammal
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016243516A
Other languages
English (en)
Inventor
Richard M. Kream
Kirk J. Mantione
George B. Stefano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2016243516A1 publication Critical patent/AU2016243516A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2016243516A 2015-03-27 2016-03-25 Methods and materials for reducing amyloid beta levels within a mammal Abandoned AU2016243516A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139178P 2015-03-27 2015-03-27
US62/139,178 2015-03-27
PCT/US2016/024295 WO2016160594A1 (en) 2015-03-27 2016-03-25 Methods and materials for reducing amyloid beta levels within a mammal

Publications (1)

Publication Number Publication Date
AU2016243516A1 true AU2016243516A1 (en) 2017-11-09

Family

ID=57006339

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016243516A Abandoned AU2016243516A1 (en) 2015-03-27 2016-03-25 Methods and materials for reducing amyloid beta levels within a mammal

Country Status (6)

Country Link
US (2) US10639322B2 (enExample)
EP (1) EP3273972A4 (enExample)
JP (1) JP2018509479A (enExample)
AU (1) AU2016243516A1 (enExample)
CA (1) CA2981138A1 (enExample)
WO (1) WO2016160594A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924597A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2134714A (en) 1936-11-25 1938-11-01 Jacob A Glassman Saccharine-aspirin tablet
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
DE19806186A1 (de) 1997-02-03 1998-11-26 Max Delbrueck Centrum Genomische Sequenz des humanen mu-Opioid-Rezeptor Genes sowie seiner Varianten, Polymorphismen und Mutationen
EP1021177A4 (en) 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
US20050085498A1 (en) 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20030159178A1 (en) 2000-02-10 2003-08-21 Peter Ulvskov Method for remodelling cell wall polysaccharide structures in plants
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
DE10045059A1 (de) 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
JPWO2002032905A1 (ja) 2000-10-20 2004-02-26 味の素株式会社 マラリア治療のための医薬組成物、ドーズおよび方法
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0117767D0 (en) 2001-07-20 2001-09-12 Unilever Plc Polymers and their synthesis
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050214413A1 (en) 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
JP3998695B2 (ja) 2005-04-22 2007-10-31 株式会社シクロケム αリポ酸水溶液及びその製造方法
DE112005001269T5 (de) 2005-04-26 2008-05-29 Versitech Ltd. Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität
US7560536B2 (en) 2005-05-18 2009-07-14 Virginia Tech Intellectual Properties, Inc. Morning glory-derived anticancer agents, and novel ipomoeassin compounds
JP4863204B2 (ja) 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
JP5247012B2 (ja) 2006-07-25 2013-07-24 雪印メグミルク株式会社 脂肪肝抑制剤
EP2106449B1 (en) 2007-01-18 2012-09-19 Novozymes A/S Method for producing potato products
JP2009007309A (ja) 2007-06-29 2009-01-15 Riken Vitamin Co Ltd α−リポ酸含有多芯型マイクロカプセル
KR101121543B1 (ko) * 2007-07-04 2012-03-06 학교법인 선목학원 벼과식물로부터 수득되는 전분 또는 식이섬유를 포함하는허혈성 질환 및 퇴행성 뇌질환의 예방 및 치료를 위한조성물
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
AU2010300391A1 (en) 2009-10-02 2012-04-26 University Of Idaho Potato products with enhanced resistant starch content and moderated glycemic response and methods thereof
KR101093413B1 (ko) 2009-10-05 2011-12-14 고려대학교 산학협력단 뇌 신경 세포 보호 활성을 갖는 고구마 추출물 및 그의 용도
EP2510014A1 (en) 2009-12-11 2012-10-17 Unilever NV Polysaccharide suitable to modulate immune response
WO2012016050A2 (en) 2010-07-28 2012-02-02 The General Hospital Corporation Chemoradiotherapy for kras-mutant colorectal cancer
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
CA2848711C (en) 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
AU2013240229B2 (en) 2012-03-28 2017-07-06 The Research Foundation For The State University Of New York Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
US9814255B2 (en) * 2012-05-20 2017-11-14 Darco Natural Products Inc. Method for producing purple sweet potato juice and dried powder
US9180212B2 (en) * 2012-05-22 2015-11-10 The Regents Of The University Of California β-amyloid plaque imaging agents
WO2014051076A1 (ja) 2012-09-28 2014-04-03 株式会社Ｂｎａ Ｂｎａクランプ法
GB201223365D0 (en) 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
CN103110657A (zh) * 2013-01-31 2013-05-22 黄仁彬 玉郎伞多糖在制备药物中的应用
CN105377271A (zh) 2013-03-15 2016-03-02 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
WO2014200969A2 (en) 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
CA2924597A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
MX2016011897A (es) 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
JP6793180B2 (ja) 2015-03-27 2020-12-02 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク 癌を治療するための方法および物質
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
AU2017234662A1 (en) 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions

Also Published As

Publication number Publication date
EP3273972A4 (en) 2018-10-31
US10639322B2 (en) 2020-05-05
WO2016160594A1 (en) 2016-10-06
JP2018509479A (ja) 2018-04-05
US20200268787A1 (en) 2020-08-27
CA2981138A1 (en) 2016-10-06
US20180078575A1 (en) 2018-03-22
EP3273972A1 (en) 2018-01-31
US11253538B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
US20170232033A1 (en) Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
US20220110965A1 (en) Methods and materials for treating diabetes or liver steatosis
US11253538B2 (en) Methods and materials for reducing amyloid beta levels within a mammal
AU2021212086A1 (en) Methods and materials for treating cancer
US20190076461A1 (en) Materials and methods for treating hypoxic conditions
EP3515210B1 (en) Materials and methods for producing and using mitochondrial preparations

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application